Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The CYP2A subfamily: function, expression and genetic polymorphism.

H Raunio1, A Rautio, O Pelkonen

  • 1Department of Pharmacology and Toxicology, University of Oulu, Finland.

IARC Scientific Publications
|September 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Future directions for monitoring and human health research for the Arctic Monitoring and Assessment Programme.

Global health action·2018
Same author

Quantitative estimation of mercury intake by toxicokinetic modelling based on total mercury levels in humans.

Environment international·2018
Same author

The xenoestrogens, bisphenol A and para-nonylphenol, decrease the expression of the ABCG2 transporter protein in human term placental explant cultures.

Molecular and cellular endocrinology·2016
Same author

Is geographical distance a barrier in the use of public primary health services among rural and urban young adults? Experience from Northern Finland.

Public health·2015
Same author

Organic anion transporter 4 (OAT 4) modifies placental transfer of perfluorinated alkyl acids PFOS and PFOA in human placental ex vivo perfusion system.

Placenta·2015
Same author

Cadmium inhibits ABCG2 transporter function in BeWo choriocarcinoma cells and MCF-7 cells overexpressing ABCG2.

Placenta·2012
Same journal

North America.

IARC scientific publications·2016
Same journal

Central and South America.

IARC scientific publications·2016
Same journal

Africa.

IARC scientific publications·2016
Same journal

Data availability and presentation.

IARC scientific publications·2016
Same journal

Age standardization.

IARC scientific publications·2016
Same journal

Data processing.

IARC scientific publications·2016
See all related articles

The CYP2A6 gene encodes an enzyme crucial for metabolizing toxins like tobacco smoke and pharmaceuticals. Genetic variations in CYP2A6 can lead to poor metabolizer phenotypes, impacting toxin processing and disease risk.

Area of Science:

  • Pharmacogenomics
  • Enzyme kinetics
  • Toxicology

Background:

  • The CYP2A6 gene is part of the human CYP2A subfamily, alongside CYP2A7 and CYP2A13.
  • CYP2A6 enzyme is primarily expressed in the liver and metabolizes clinically significant compounds, including pharmaceuticals, procarcinogens, and tobacco smoke constituents.
  • Coumarin serves as a high-affinity substrate for CYP2A6, enabling its use in phenotyping tests.

Purpose of the Study:

  • To review the current understanding of the CYP2A6 gene and its enzyme.
  • To highlight the significance of CYP2A6 in metabolizing various xenobiotics.
  • To underscore the need for further research into CYP2A6 polymorphism and its association with diseases.

Main Methods:

  • Literature review of studies on CYP2A6 gene and enzyme.

Related Experiment Videos

  • Analysis of coumarin 7-hydroxylation as a phenotyping test.
  • Examination of known CYP2A6 mutant alleles (CYP2A6*2, CYP2A6*3) and their association with poor metabolizer phenotypes.

    • Main Results:

    • Two mutant alleles, CYP2A6*2 and CYP2A6*3, have been identified.
    • Homozygosity for these mutations results in a poor metabolizer (PM) phenotype, characterized by impaired coumarin 7-hydroxylation.
    • Limited information exists regarding CYP2A6 inducibility and regulation, though mouse orthologue studies suggest novel induction pathways.

    Conclusions:

    • CYP2A6 genetic polymorphism is a recent discovery with unknown associations with diseases or adverse outcomes.
    • Further studies are warranted to explore the link between variant CYP2A6 alleles and health outcomes, given the enzyme's role in metabolizing numerous toxins.
    • Understanding CYP2A6 variations is critical for personalized medicine and assessing risks associated with environmental exposures.